Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
ARS Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 3 | -$0.47 | -$0.21 | -$0.34 |
| Q2 2025 | 1 | -$0.42 | -$0.42 | -$0.42 |
| Q3 2025 | 1 | -$0.34 | -$0.34 | -$0.34 |
| Q4 2025 | 1 | -$0.23 | -$0.23 | -$0.23 |
| Q1 2026 | 1 | -$0.26 | -$0.26 | -$0.26 |
| Q2 2026 | 1 | -$0.24 | -$0.24 | -$0.24 |
| Q3 2026 | 1 | -$0.02 | -$0.02 | -$0.02 |
| Q4 2026 | 1 | -$0.01 | -$0.01 | -$0.01 |
ARS Pharmaceuticals, Inc. Earnings Date And Information
ARS Pharmaceuticals, Inc. last posted its earnings results on Thursday, March 20th, 2025. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $-0.04 by $0.56. The company had revenue of 86.58 M for the quarter and had revenue of 89.15 M for the year. ARS Pharmaceuticals, Inc. has generated $0 earnings per share over the last year ($0.0781 diluted earnings per share) and currently has a price-to-earnings ratio of 181.8. ARS Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 9th, 2025 based on prior year's report dates.
ARS Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/20/2025 | Q4 2024 | -$0.04 | $0.52 | 0.56 | $5.65 M | $86.58 M |
| 12/06/2024 | Q3 2024 | N/A | -$0.20 | N/A | $575,000 | $2.07 M |
| 08/06/2024 | Q2 2024 | -$0.12 | -$0.13 | -0.01 | $1.00 M | $500,000 |
| 05/09/2024 | Q1 2024 | -$0.11 | -$0.11 | 0 | $1.00 M | $0 |
| 03/21/2024 | Q4 2023 | -$0.14 | -$0.07 | 0.07 | N/A | $-30,000 |
| 11/09/2023 | Q3 2023 | -$0.18 | -$0.16 | 0.02 | N/A | $0 |
| 08/10/2023 | Q2 2023 | -$0.17 | -$0.18 | -0.01 | N/A | $10,000 |
| 05/15/2023 | Q1 2023 | -$0.17 | -$0.12 | 0.05 | N/A | $20,000 |
| 03/23/2023 | Q4 2022 | -$0.13 | -$0.15 | -0.02 | N/A | $-1,316,000 |
| 09/29/2022 | Q3 2022 | N/A | -$0.07 | N/A | N/A | $189,000 |
| 08/11/2022 | Q2 2022 | -$0.48 | -$0.06 | 0.42 | N/A | $464,000 |
| 03/31/2022 | Q1 2022 | -$0.70 | -$0.08 | 0.62 | N/A | $663,000 |
| 03/31/2022 | Q4 2021 | -$0.70 | -$0.67 | 0.03 | N/A | $754,000 |
| 09/29/2021 | Q3 2021 | N/A | -$0.65 | N/A | N/A | $528,000 |
| 06/29/2021 | Q2 2021 | N/A | -$0.70 | N/A | N/A | $2.11 M |
| 03/30/2021 | Q1 2021 | N/A | -$0.54 | N/A | N/A | $2.11 M |
| 12/29/2020 | Q4 2020 | N/A | -$0.38 | N/A | N/A | $0 |
| 06/29/2020 | Q2 2020 | N/A | -$0.19 | N/A | N/A | $0 |
| 03/30/2020 | Q1 2020 | N/A | -$0.16 | N/A | N/A | $0 |
| 12/30/2019 | Q4 2019 | N/A | -$0.21 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
ARS Pharmaceuticals, Inc. Earnings: FAQ's
ARS Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, May 9th, 2025 based offlast year's report dates.
In the previous quarter, ARS Pharmaceuticals, Inc. (:SPRY) reported $0.52 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.04 by $0.56.
The conference call for ARS Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for ARS Pharmaceuticals, Inc.'s latest earnings report can be read online.
ARS Pharmaceuticals, Inc. (:SPRY) has a recorded annual revenue of $89.15 M.
ARS Pharmaceuticals, Inc. (:SPRY) has a recorded net income of $8.00 M.ARS Pharmaceuticals, Inc. has generated $0.0825 earnings per share over the last four quarters.
ARS Pharmaceuticals, Inc. (:SPRY) has a price-to-earnings ratio of 181.8 and price/earnings-to-growth ratio is 1.57.